Phase 4 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have open-angle glaucoma, or are suspected of having open-angle glaucoma, in the eye being studied
- People who have had their natural lens replaced with an artificial lens (such as after cataract surgery) in the eye being studied, and who meet a specific eye health measurement called a Shafer grading of 3 or higher (confirm with trial site)
- People who have been using 3 or fewer daily glaucoma eye drops for at least 6 months, including one specific type of drop called a preserved prostaglandin analogue, taken at night
- People who have been taking their eye drops consistently — missing no more than 20% of doses in the last month, and having taken their last dose within the past 24 hours
- People who have small surface scratches or worn patches on the front of their eye (the cornea), measured above a score of 3 on a standard eye health scale
Who may not be able to join:
- People who have a disease affecting the retina (the light-sensitive layer at the back of the eye), such as wet macular degeneration, advanced diabetic eye disease, or a blocked retinal vein
- People currently using medications — either as eye drops or taken by mouth — that suppress or modify the immune system, such as steroids, cyclosporine, lifitegrast, or antihistamines
- People currently using preservative-free eye drops to lower eye pressure
- People for whom a specific type of eye implant (an intracameral bimatoprost implant) would not be medically appropriate for any reason (confirm with trial site)
- People with a history of recurring eye inflammation or allergic eye conditions, such as allergic or atopic conjunctivitis
- People who have had a partial or full corneal transplant at any time
- People who have had eye surgery — either inside the eye or certain eyelid procedures — within the past 6 months
- People who have had a specific type of glaucoma surgery underneath the eye's surface membrane (such as trabeculectomy, an aqueous shunt, or a Xen implant) within the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Swarup S Swaminathan, MD, University of Miami
Phone: 305-326-6387
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Caspase-1 mRNA Expression Following Durysta Injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.